IMPROVING PAIN TREATMENT
Developing innovative biopharmacueticals for patients with neuropathic pain
PAIN
A DISEASE MODYFYING APPROACH
We are working with a unique family of neurotrophic factors for the treatment of peripheral neuropathic pain.
Our lead candidate, HB-086 is in early preclinical development, and targets underserved neuropathic pain indications. The family of neurotrophic factors may prove beneficial in a varity of CNS disorders .
THERAPEUTIC AREAS
NEUROPATHIC PAIN
Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system. Triggers include endocrine disorders, viral infections injury or nerve toxins (e.g. chemotherapy).
NEURODEGENERATIVE DISORDERS
Degenerative nerve disorders are a broad spectrum of progressive diseases characterized by motor dysfunction, behavioral and personality changes and cognitive decline.
HEARING LOSS
Hearing loss may be caused by a number of factors, including: genetics, ageing, exposure to noise, infections, trauma, and certain medications or toxins.
BETTER LIVES
Currently approved drugs for neuropathic pain provide moderate symptomatic relief for a subset of patients. Their use and dosing levels are limited by side effects.
Our focus are
- Developing novel biopharmaceuticals
- Treating and preventing neuropathic pain
- Providing safe and well-tolerated biologics to patients
- Exploring HB-086 and HB-097 in CNS disorders
.jpg?etag=W%2F%229b78-58d27459%22&sourceContentType=image%2Fjpeg&ignoreAspectRatio&resize=261%2B160&extract=80%2B0%2B160%2B159&quality=85)
.jpg?etag=W%2F%229b78-58d27459%22&sourceContentType=image%2Fjpeg&ignoreAspectRatio&resize=259%2B159&extract=0%2B0%2B160%2B159&quality=85)
CONTACT US
c/o Cobis
Ole Maaløes vej 3,
DK-2200
keap@hobatherapeutics.com
Tel: +45 31101285
Hoba Therapeutics
Disease modifying treatments for neuropathic pain